A link between depression and bone metabolism: What are the implications for treatment?

Expert Review of Endocrinology and Metabolism

Volumn 4, Issue 3, 2009, Pages 199-202

  Mezuk, Briana ^a   Hill, Sherita ^b,c  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYERGOCALCIFEROL; ADRENERGIC RECEPTOR BLOCKING AGENT; ALKALINE PHOSPHATASE BONE ISOENZYME; ANTIDEPRESSANT AGENT; CALCIUM; GLITAZONE DERIVATIVE; INTERLEUKIN 1; INTERLEUKIN 6; LOOP DIURETIC AGENT; OSTEOCALCIN; PARATHYROID HORMONE; SEROTONIN UPTAKE INHIBITOR; TELOPEPTIDE; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

AGING; BONE DEMINERALIZATION; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE TURNOVER; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DRUG MECHANISM; EDITORIAL; FRACTURE; HORMONAL REGULATION; HUMAN; HYPERTENSION; MENOPAUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PATIENT MONITORING; PHYSICAL ACTIVITY; POLYPHARMACY; PRIORITY JOURNAL; RISK FACTOR; TREATMENT PLANNING; VITAMIN SUPPLEMENTATION;

EID: 70149102481     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/eem.09.2     Document Type: Editorial

References (50)

1. Eaton WW. Medical and Psychiatric Comorbidity Over the Lifecourse. American Psychiatric Publishing Inc., VA, USA (2005).
2. Cizza G, Ravn P, Chrousos G. Depression: a major, unrecognized risk factor for osteoporosis? Trends Endocrinol. Metab. 12, 198-203 (2001).
3. Mezuk B, Eaton WW, Golden SH. Depression and osteoporosis: epidemiology and potential mediating pathways. Osteoporos. Int. 19, 1-12 (2008).
4. Eaton WW, Shao H, Nestadt G et al. Population-based study of first onset and chronicity in major depressive disorder. Arch. Gen. Psychiatry 65, 513-520 (2008).
5. WHO. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of the WHO Study Group. Word Health Organ. Tech. Rep. Ser. 843, 1-126 (1994).
6. Raisz L. Physiology and pathophysiology of bone remodeling. Clin. Chem. 48, 1353-1358 (1999).
7. Williams LJ, Pasco JA, Jacka FN et al. Depression and bone metabolism. Psychother. Psychosom. 78, 16-25 (2009).
8. Licinio J, Wong M. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-response systems, and contribute to neurotoxicity and neuroprotection. Mol. Psychiatry 44, 317-327 (1999).
9. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos G. The pathophysiologic roles of interleukin-6 in human disease. Ann. Intern. Med. 128(2), 127-137 (1998).
10. De Berardis D, Campanella D, Gambi F et al. The role of C-reactive protein in mood disorders. Int. J. Immunopathol. Pharmacol. 19(4), 721-725 (2006).
11. Taylor MJ, Goodwin GM. Long-term prophylaxis in bipolar disorder. CNS Drugs 20, 303-310 (2006).
12. Romas E, Martin T. Cytokines in the pathogenesis of osteoporosis. Osteoporos. Int. 7, S47-S53 (1997).
13. Carroll BJ, Curtis GC, Davies BM et al. Urinary free cortisol excretion in depression. Psychol. Med. 6(1), 43-50 (1976).
14. Watson S, Gallegher P, Ritchie J et al. Hypothalamic - pituitary - adrenal axis function in patients with bipolar disorder. Br. J. Psych. 184, 496-502 (2004).
15. Kann P, Laudes M, Piepkorn B et al. Suppressed levels of serum cortisol following high-dose oral dexamethasone administration differ between healthy postmenopausal females and patients with established primary vertebral osteoporosis. Clin. Rheumatol. 20(1), 25-29 (2001).
16. Reynolds RM, Dennison EM, Walker BR et al. Cortisol secretion and rate of bone loss in a population-based cohort of elderly men and women. Calcif. Tissue Int. 77, 134-138 (2005).
17. Dennison E, Hindmarsh P, Fall C et al. Profiles of endogenous circulating cortisol and bone mineral density in healthy elderly men. J. Clin. Endocrinol. Metab. 84, 3058-3063 (1999).
18. Lake CR, Pickar D, Ziegler MG et al. High plasma norepinephrine levels in patients with major affective disorder. Am. J. Psychiatry 139(10),1315-1318 (1982).
19. Maes M, Vandewoude M, Schotte C et al. Positive relationship between the catecholaminergic turnover and the DST results in depression. Psychol. Med. 20(3), 493-499 (1990).
20. Rehman H, Masson E. Neuroendocrinology of female aging. Gend. Med. 2, 41-56 (2005).
21. Carnahan R, Perry P. Depression in aging men: the role of testosterone. Drugs Aging 21, 361-376 (2004).
22. Shoback D, Marcus R, Bikle D. Metabolic bone disease. In: Basic and Clinical Endocrinology. Greenspan F, Gardner D (Eds). Lange Medical Books/McGraw-Hill, NY, USA 295-361 (2004).
23. Khosla S, Melton LJ 3rd, Atkinson EJ et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J. Clin. Endocrinol. Metab. 83(7), 2266-2274 (1998).
24. Herrán A, Amado JA, García-Unzueta MT et al. Increased bone remodeling in first-episode major depressive disorder. Psychosom. Med. 62, 779-782 (2000).
25. Kahl KG, Greggersen W, Rudolf S et al. Bone mineral density, bone turnover, and osteoprotegerin in depressed women with and without borderline personality disorder. Psychosom. Med. 68, 669-674 (2006).
26. Altindag O, Altindag A, Asoglu M et al. Relation of cortisol levels and bone mineral density among premenopausal women with major depression. Int. J. Clin. Pract. 61, 416-420 (2007).
27. Michelson D, Stratakis C, Hill L et al. Bone mineral density in women with depression. N. Engl. J. Med. 335, 1176-1181 (1996).
28. Yazici K, Akinci A, Sütçü A, Ozçakar L. Bone mineral density in premenopausal women with major depressive disorder. Psychiatry Res. 117, 271-275 (2003).
29. Eskandari F, Martinez PE, Torvik S et al. Low bone mass in premenopausal women with depression. Arch. Intern. Med. 167, 2329-2336 (2007).
30. Petronijevic M, Petronijevic N, Ivkovic M et al. Low bone mineral density and high bone metabolism turnover in premenopausal women with unipolar depression. Bone 42, 582-590 (2008).
31. Kavuncu V, Kuloglu M, Kaya A et al. Bone metabolism and bone mineral density in premenopausal women with mild depression. Yonsei Med. J. 43, 101-108 (2002).
32. Alexopoulos GS, Katz IR, Reynolds CF et al. The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients. Postgrad. Med. 1-86 (2001).
33. Battaglino R, Vokes M, Schulze-Späte U et al. Fluoxetine treatment increases trabecular bone formation in mice. J. Cell. Biochem. 100, 1387-1394 (2007).
34. Warden SJ, Haney EM. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from in vitro and animal-based studies. J. Musculoskelet. Neuronal Interact. 8, 121-132 (2008).
35. Bonnet N, Bernard P, Beaupied H et al. Various effects of antidepressant drugs on bone microarchitectecture, mechanical properties and bone remodeling. Toxicol. Appl. Pharmacol. 221(1), 111-118 (2007).
36. Battaglino R, Fu J, Späte U et al. Serotonin regulates osteoclast differentiation through its transporter. J. Bone Miner. Res. 19(9), 1420-1431 (2004).
37. Warden SJ, Nelson IR, Fuchs RK, Bliziotes MM, Turner CH. Serotonin (5-hydroxytryptamine) transporter inhibition causes bone loss in adult mice independently of estrogen deficiency. Menopause 15(6), 1176-1183 (2008).
38. Mezuk B, Eaton WW, Golden SH et al. Depression, antidepressants and bone mineral density in a population-based cohort. J. Gerontol. A. Biol. Sci. Med. Sci. 63, 1410-1415 (2008).
39. Diem SJ, Blackwell TL, Stone KL et al. The study of osteoporotic fractures. Use of antidepressants and rates of hip bone loss in older women: Arch. Intern. Med. 167, 1240-1245 (2007).
40. Bonnet N, Beaupied H, Vico L et al. Combined effects of exercise and propranolol on bone tissue in ovariectomized rats. J. Bone Min. Res. 22(4), 578-588 (2007).
41. Veehof L, Stewart R, Haaijer-Ruskamp F et al. The development of polypharmacy. A longitudinal study. Fam. Pract. 17(3), 261-267 (2000).
42. Laroche ML, Charmes JP, Nouaille Y et al. Is inappropriate medication use a major cause of adverse drug reactions in the elderly? Br. J. Clin. Pharmacol. 63, 177-186 (2007).
43. Mort JR, Aparasu RR. Prescribing potentially inappropriate psychotropic medications to the ambulatory elderly. Arch. Intern. Med. 160(18), 2825-2831 (2000).
44. Lindström K, Ekedahl A, Carlsten A et al. Can selective serotonin inhibitor drugs in elderly patients in nursing homes be reduced? Scand. J. Prim. Health Care 25(1), 3-8 (2007),
45. Takkouche B, Montes-Martinez A, Gill S, Etminan M. Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf. 30, 171-184 (2007).
46. Vestergaard P. Fracture risks of antidepressants. Expert Rev. Neurother. 9(1), 137-141 (2009).
47. Mezuk B, Eaton W, Albrecht S, Golden SH. Depression and Type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 31, 2383-2390 (2008).
48. Rugulies R. Depression as a predictor for coronary heart disease: a review and meta-analysis. Am. J. Prev. Med. 23, 51-61 (2002).
49. Markowitz S, Friedman MA, Arent SM. Understanding the relation between obesity and depression: causal mechanisms and implications for treatment. Clin. Psychol. Sci. Pract. 15, 1-20 (2008).
50. Buist DS, LaCroix AZ, Black DM et al. Inclusion of older women in randomized clinical trials: factors associated with taking study medication in the fracture intervention trial. J. Am. Geriatr. Soc. 48(9), 1126-1131 (2000).